Amplifon advances GN Hearing deal: Amplifon stock sits 17.98 percent below target

Published on 10/16/2026 at 10:17 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Morgan Stanley raised its target to EUR 14.96 on October 9, 2026. Amplifon stock costs EUR 12.27 on October 16, 2026 versus EUR 12.20.

Deal timetable and valuation

On October 9, 2026, the GN Hearing transaction entered European merger review.
Morgan Stanley set a EUR 14.96 target on October 9, 2026.
Amplifon stock trades at EUR 12.27 at 10:09 a.m. CEST at Lang & Schwarz on October 16, 2026, 0.57 percent above the Xetra close of October 15, 2026.

Bauhaus-Poster mit geometrischen Formen und dem Wort HEALTH in Blockschrift — Bauhaus-Poster mit geometrischen Formen und Sektor-Text repräsentiert Amplifon S.p.A., ISIN IT0004056880, im Bereich Medizintechnik, Illustration mit AI erstellt.

Amplifon stock (ISIN IT0004056880) was trading at EUR 12.27 at Lang & Schwarz on October 16, 2026 at 10:09 a.m. CEST, up 0.57 percent versus the Xetra close of October 15, 2026 at EUR 12.20. The latest corporate development is the regulatory review of Amplifon's planned acquisition of GN Hearing, reported by EU Law Live on October 9, 2026.

GN Hearing moves toward approval

The European Commission received notification of the proposed concentration on October 1, 2026. The transaction would give Amplifon sole control of GN Hearing through a purchase of shares, according to EU Law Live.

The transaction has built through three dated steps. On March 16, 2026, Amplifon announced an agreement valued at EUR 2.30 billion, including EUR 1.69 billion in cash and 56 million new Amplifon shares, as reported by Rankia. On September 17, 2026, Amplifon's board resolved to convene shareholders to approve the reserved capital increase tied to the transaction, according to Amplifon. On October 9, 2026, the European Commission notification put the deal into formal merger review.

What does October 29 bring?

October 29, 2026 combines two company dates: Amplifon is scheduled to publish third-quarter results and hold the shareholders meeting on the GN Hearing capital increase. The meeting notice was issued by Amplifon, while finanzen.net reported consensus estimates of EUR 572.70 million in third-quarter revenue, up 1.67 percent from EUR 563.30 million.

Amplifon's first-half 2026 revenue reached EUR 1.19 billion, up 1.30 percent at constant exchange rates, while organic growth reached 3.50 percent, according to Rankia. Management also confirmed organic growth above 3.00 percent for 2026 and an adjusted EBITDA margin increase of 100 basis points.

Quote stays below the target

Morgan Stanley confirmed its Overweight rating and raised its target from EUR 14.90 to EUR 14.96 on October 9, 2026, according to Teleborsa. The target is 17.98 percent above the Lang & Schwarz price, leaving the merger timetable and the next results as the clearest dated tests for the investment case.

Quote and market value

Amplifon has a market capitalization of EUR 2.7 billion as of October 16, 2026. Its 52-week range is EUR 7.84 to EUR 15.84, placing the current quote below the yearly high while the GN Hearing transaction advances through regulatory and shareholder milestones. The further course of trading is shown by the continuously updated real-time quote of Amplifon stock.